Bayer has announced successful Phase III OCEANIC STROKE trial results for its oral factor XIa inhibitor asundexian, showing significant ischemic stroke risk reduction versus placebo when combined with antiplatelet therapy in patients with non-cardioembolic ischemic stroke or high risk transient ischemic attack. The 50 mg once-daily regimen met primary efficacy and safety endpoints without increased ISTH major bleeding risk compared to antiplatelet therapy alone. The global study addresses recurrent stroke prevention where 20% of survivors experience subsequent events within 5 years despite current standard of care, with recurrent ischemic strokes carrying higher disability and mortality rates than initial events.
Factor XIa represents a novel target in coagulation cascade, with limited role in physiological haemostasis but involvement in pathological thrombosis formation. Asundexian's mechanism selectively inhibits factor XIa, reducing pathological clot formation without significantly impacting bleeding risk. Bayer pharmaceuticals research head Christian Rommel highlighted this potential new approach for protecting patients from recurrent strokes, following the 2023 discontinuation of the OCEANIC AF trial in atrial fibrillation patients, where asundexian demonstrated inferior efficacy versus apixaban based on an independent data monitoring committee recommendation. The successful stroke prevention trial supports a differentiated profile for thromboprophylaxis in distinct clinical settings.

According to PharmCube's NextBiopharm® database, asundexian is the most developed asset among 15 active factor XIa inhibitor programs worldwide. Click here to request a free trial for NextBiopharm®.